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Purpose: The short insulin tolerance test is a simple and
reliable method of estimating insulin sensitivity. This study
was designed to compare the insulin sensitizing effects of
thiazolidinediones (TZDs) on the degree of insulin resistance,
determined by a short insulin tolerance test (Kitt) in type 2
diabetic patients. Patients and Methods: Eighty-three subjects
(mean age = 57.87 ±10.78) with type 2 diabetes mellitus were
enrolled and received daily one dose of rosiglitazone (4 mg)
or pioglitazone (15 mg). The mean follow-up duration was
25.39 ± 9.66 months. We assessed insulin sensitivity using
HOMA-IR and the short insulin tolerance test before and after
TZDs treatment. Results: When we compared patients’ char-
acteristics before and after TZDs treatment, the mean fasting
glucose level was significantly decreased (183.27 ± 55.04 to
137.35 ± 36.42 mg/dL, p < 0.001) and the mean HbA1C level
was significantly decreased (9.24 ± 1.96 to 8.11 ± 1.39%, p <
0.001). Also, Kitt values were significantly increased (2.03 ±
1.14 to 2.67 ± 0.97%/min, p = 0.003), whereas HOMA-IR was
significantly decreased (2.98 ± 0.68 to 1.04 ± 0.24, p < 0.05).
When classifying insulin resistance by Kitt values, insulin
resistant subjects’ values were increased (< 2.5 %/min; 1.51±
0.53%/min to 2.63 ±0.88, p< 0.001), whereas the values
decreased in insulin sensitive subjects ( 2.5%/min; 3.50 ±
0.75%/min to 2.75 ± 1.12%/min, p = 0.002). Conclusion: The
glucose lowering effects of TZDs by improving insulin
resistance could be determined by using Kitt. However, Kitt
may be a beneficial tool to determine TZDs’ effects only when
patients’ Kitt values are less than 2.5%/min.
Key Words: Thiazolidinediones, insulin sensitivity, short
insulin tolerance test, type 2 diabetes
INTRODUCTION
Insulin resistance is the main pathologic mech-
anism of type 2 diabetes mellitus and cardio-
vascular disease.
1-3 For evaluation of insulin sensi-
tivity, the euglycemic hyperinsulinemic clamp is the
gold standard method in both animal and human.
4
However, this technique is very difficult and com-
plex and has been replaced by other simple and
rapid methods such as the Homeostatic Model
Assessment (HOMA) and the short insulin tole-
rance test (Kitt).
5 Kitt was shown to have a close
correlation with glucose clamp studies and could
be suitable for estimating insulin sensitivity over
a long period.
6
Thiazolidinediones (TZDs) are a more recently
discovered antidiabetic agents thought to increase
peripheral glucose utilization or inhibit hepatic
gluconeogenesis by binding the nuclear peroxi-
some proliferators-activated receptors gamma
(PPAR- ). γ
7-9 The beneficial effects of TZDs on
glycemic control by improving the insulin resistan-
ce in type 2 diabetic patients are already known,
but no data are available to determine the effects
of TZDs by Kitt.
10,11
In this study, we investigated the insulin sensi-
tizing effects of TZDs in Korean type 2 diabetic
patients by using Kitt.
PATIENTS AND METHODS
Subjects
Eighty-three subjects (mean age = 57.87 ± 10.78)
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who visited the diabetes clinic at Wonju Christian
Hospital, South Korea from January 2004 to
December 2006 were enrolled. Patients with type
2 diabetes who were inadequately treated with
sulfonylurea or metformin (glimepiride, 50/83;
gliclazide, 15/83; metformin, 18/83) were included
in this study. Patients daily received either 4 mg
of rosiglitazone or 15 mg of pioglitazone in a single
dose regimen (rosiglitazone, 60/83; pioglitazone,
23/83), and medication was not changed through-
out the study. Mean follow-up duration was 25.39
± 9.66 months.
Assessment of insulin resistance
Insulin resistance was evaluated by means of
Kitt and HOMA-IR. Insulin resistance was deter-
mined in all subjects at baseline and after 2 years.
Plasma glucose disposal rate (Kitt; %/min) was
calculated as previously described
6: Kitt was the
ratio between 0.693 and t1/2, where t1/2 is the
time necessary to reduce the basal glucose level by
one half. The t1/2 value was calculated from the
slope of least square analysis of the glycemic con-
centrations, starting at the 3rd minute until the
15th minute after intravenous regular insulin
injection (0.1 U/kg). We set our definition of in-
sulin resistant state as a Kitt value below 2.5%/min,
according to a previous study.
12 HOMA-IR was
calculated using fasting serum insulin (pmol/L)
and fasting plasma glucose (mmol/L; fasting in-
sulin fasting glucose ÷ 22.5).
13
Clinical and biochemical measurements
Height, weight, waist circumference, hip circum-
ference, waist-hip ratio (WHR), and body mass
index (BMI) were measured in all subjects. BMI
was calculated as weight divided by height squar-
ed (kg/m
2). Waist circumference was measured
with soft tape at midway between the lowest rib
and the iliac crest. The hip circumference was
measured at the widest part of the gluteus region.
The waist-to-hip ratio was then calculated. Systolic
and diastolic blood pressure (SBP and DBP) was
taken after 5 minutes rest and cessation of smoking
by an automatic sphygmomanometer. Blood sam-
ples for fasting glucose, fasting insulin (RIA, Cobra
II, Packard, MI, USA), HbA1C (high performance
liquid chromatography, variant II, Bio-Rad,
Richmond, CA, USA), total cholesterol (TBA-200FR,
Hitachi 7170, Tokyo, Japan), triglyceride, high-
density lipoprotein cholesterol, and low-density
lipoprotein cholesterol were collected after more
than 10 hours of overnight fasting.
Statistical analysis
Data are expressed as means ± standard de-
viations unless stated otherwise. We used the
Student's t test to compare characteristics between
men and women and the values between insulin
resistance and insulin sensitive states, as defined
by Kitt. Paired t-test was used to compare values
obtained before and after TZDs administration. A
chi-square test was performed to validate dif-
ferences in insulin resistance when variables were
stratified. Pearson's correlation coefficient was
used to establish the association between Kitt and
clinical and laboratory parameters of subjects. All
analyses were performed using the Windows-
based SPSS statistical package (ver. 12.0, Chicago,
IL, USA), and p < 0.05 were considered significant.
RESULTS
Clinical and biochemical characteristics of subjects
The main characteristics of study subjects are
shown in Table 1. Male subjects were characterized
by greater weight, waist circumference, waist-hip-
ratio, and lower HDL cholesterol levels. Average
BMI was 23.16 ± 2.51 kg/m
2 (males 23.17 ± 2.51
kg/m
2, females 23.14 ± 2.56 kg/m
2), and waist
circumference was 81.97 ± 7.04 cm (males 83.49 ±
6.90 cm, females 78.98 ± 6.43). Insulin sensitivity
markers were not different between males and
females.
Parameter changes
Subjects showed improved glycemic control
after the addition of TZDs to their oral hypogly-
cemic drugs. As shown in Table 2, there were
significant changes in fasting glucose (183.28 ±
55.04 mg/dL to 137.34 ± 36.4 mg/dL, p < 0.001)
and HbA1C levels (9.24 ± 1.96% to 8.11 ± 1.39%, pThiazolidinediones and Short Insulin Tolerance Test
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< 0.001) after 2-year treatment with TZDs. Both
body weight and BMI were significantly increased
when compared with baseline values. Also, both
waist and hip circumference increased significantly.
No significant changes were observed in total
cholesterol, LDL-cholesterol, and triglyceride levels.
However, HDL-cholesterol levels significantly
increased at 24 months when compared with
baseline values (44.04 ± 11.17 mg/dL to 49.69 ±
14.97 mg/dL, p < 0.001; Table 2).
TZDs-induced improvement in insulin sensiti-
vity measured by both Kitt and HOMA-IR was
statistically significant (2.03 ± 1.14%/min to 2.67 ±
0.97%/min, p = 0.003 and 3.62 ± 2.98 to 1.61 ± 1.04,
p = 0.012; Table 2). When the subjects were divided
into insulin sensitive and resistant groups by base-
line Kitt values, the changes of fasting glucose,
HbA1C, and lipid profile were consistent with total
subjects (Table 3). However, Kitt values were in-
creased in insulin resistant subjects (1.51 ± 0.53%/
min to 2.63 ± 0.88, p < 0.001) and decreased in
insulin sensitive subjects (3.50 ± 0.75%/min to 2.75
± 1.12%/min, p = 0.002; Table 3 and Fig. 1). In
contrast, HOMA-IR was significantly decreased in
both insulin resistance and sensitive subjects,
defined by baseline Kitt values (Table 2).
DISCUSSION
It is well known that TZDs were efficacious in
improving glycemic control and reducing HbA1C
Table 1. Clinical and Biochemical Characteristics of Subjects
Total Male (n = 45) Female (n = 38) p value
Age (yrs) 57.87 ± 10.78 58.01 ± 10.83 57.60 ± 10.86 0.871
Duration (yrs) 8.30 ± 7.41 8.04 ± 7.63 8.84 ± 7.06 0.658
Height (cm) 163.25 ± 8.27 167.75 ± 5.07 154.40 ± 5.82 < 0.001
Weight (kg) 61.95 ± 9.45 65.37 ± 8.55 55.23 ± 7.37 < 0.001
BMI (kg/m
2) 23.16 ± 2.51 23.17 ± 2.51 23.14 ± 2.56 0.960
Waist circumference (cm) 81.97 ± 7.04 83.49 ± 6.90 78.98 ± 6.43 0.005
Hip circumference (cm) 92.21 ± 5.79 92.97 ± 5.39 90.71 ± 6.35 0.114
Waist-hip-ratio 0.89 ± 0.05 0.90 ± 0.05 0.87 ± 0.04 0.012
SBP (mmHg) 129.84 ± 14.85 128.42 ± 13.72 133.46 ± 17.46 0.363
DBP (mmHg) 74.67 ± 11.94 74.30 ± 11.89 75.61 ± 12.50 0.748
Total cholesterol (mg/dL) 186.84 ± 34.66 184.69 ± 32.33 191.07 ± 39.12 0.461
Triglyceride (mg/dL) 146.10 ± 75.72 150.91 ± 79.04 136.67 ± 69.14 0.402
HDL-cholesterol (mg/dL) 44.11 ± 11.12 42.31 ± 10.66 47.64 ± 11.35 0.044
LDL-cholesterol (mg/dL) 114.04 ± 30.01 112.20 ± 26.93 117.66 ± 35.57 0.436
Fasting glucose (mg/dL) 183.28 ± 55.04 188.32 ± 56.41 173.36 ± 51.78 0.244
HbA1C (%) 9.20 ± 1.96 9.73 ± 2.22 8.92 ± 1.77 0.100
Kitt (%/min) 2.03 ± 1.14 2.04 ± 1.18 2.00 ± 1.04 0.240
HOMA-IR 3.62 ± 2.98 3.11 ± 1.56 5.05 ± 5.36 0.222
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low
density lipoprotein; Kitt, rate constant for glucose disappearance in the insulin tolerance test; HOMA-IR, homeostasis assessment
method for insulin resistance.
Values are presented as mean ± standard deviation.Mi Young Lee, et al.
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Fig. 1. The changes of Kitt values according to insulin resistant status defined by baseline Kitt values. Kitt values were
significantly improved in subjects with insulin resistance. However, the Kitt values did not improve in subjects without
insulin resistance.
Table 2. Anthropometric Data and Biochemical Characteristics at both Baseline and Follow-up
Total (n = 83)
Baseline Follow-up p value
Weight (kg) 61.95 ± 9.45 63.11 ± 9.60 0.020
BMI (kg/m
2) 23.16 ± 2.51 23.74 ± 2.63 < 0.001
Waist circumference (cm) 81.97 ± 7.04 82.21 ± 7.63 0.048
Hip circumference (cm) 92.21 ± 5.79 93.36 ± 5.17 0.016
Waist-hip-ratio 0.89 ± 0.04 0.87 ± 0.05 0.090
SBP (mmHg) 129.84 ± 14.85 126.89 ± 12.52 0.086
DBP(mmHg) 74.67 ± 11.94 72.39 ± 9.72 0.207
Total cholesterol (mg/dL) 186.78 ± 34.87 187.67 ± 39.94 0.857
Triglyceride (mg/dL) 146.90 ± 75.84 144.77 ± 77.44 0.803
HDL-cholesterol (mg/dL) 44.04 ± 11.17 49.69 ± 14.97 < 0.001
LDL-cholesterol (mg/dL) 108.37 ± 35.79 114.04 ± 30.01 0.219
Fasting glucose (mg/dL) 183.28 ± 55.04 137.34 ± 36.42 < 0.001
HbA1C (%) 9.24 ± 1.96 8.11 ± 1.39 < 0.001
Kitt (%/min) 2.03 ± 1.14 2.67 ± 0.97 0.003
HOMA-IR 3.62 ± 2.98 1.61 ± 1.04 0.012
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density
lipoprotein; Kitt, rate constant for glucose disappearance in the insulin tolerance test; HOMA-IR, homeostasis assessment method
for insulin resistance.
Values are presented as mean ± standard deviation.Thiazolidinediones and Short Insulin Tolerance Test
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by insulin sensitizing action on muscle, adipose
tissue, and liver.
10,11,14-17 Our data showed that
TZDs treatment improved insulin sensitivity ap-
proved by both Kitt and HOMA-IR methods in
type 2 diabetic patients who had been inadequately
treated with sulfonylurea or metformin.
It was reported that metformin or sulfonylurea
combined with either pioglitazone or rosiglitazone
significantly improve glycemic control.
18,19 However,
the combination of metformin or sulfonylurea with
pioglitazone is associated with significant improve-
ment in lipid and lipoprotein levels, whereas the
rosiglitazone combination does not show a signifi-
cant effect on lipid metabolism. In this study, we
did not compare the effects between pioglitazone
and rosiglitazone. However, fasting glucose and
HbA1C levels were significantly improved, and
lipid profiles except for HDL cholesterol levels
were not changed after treatment with both piogli-
tazone and rosiglitazone compared with baseline
values. We think that TZDs' effects on lipid meta-
bolism should further be assessed in prospective
trials.
Although several studies have provided strong
evidence that TZDs may improve -cell func β -
tion,
20-22 the major effects of TZDs are mediated via
their insulin sensitizing effects on muscle and liver
by binding to PPAR- . γ
7,8,14-17 Previously, the insulin
sensitizing effects of TZDs have been assessed by
either euglycemic hyperinsulinemic clamp
16,23-25 or
HOMA index.
18,19,26,27 Although the euglycemic
hyperinsulinemic clamp is often referred to as the
gold standard test, this technique is time-consum-
ing and difficult to perform.
28 Consequently, vari-
Table 3. Parameter Changes according to Insulin Resistance as Defined by Baseline Kitt Values
Subjects of baseline Kitt < 2.5 (n = 48) Subjects of baseline Kitt 2.5 (n = 35)
Baseline Follow-up p value Baseline Follow-up p value
Weight (kg) 62.26 ± 9.06 63.31 ± 9.48 0.005 61.46 ± 10.23 62.76 ± 9.97 0.027
BMI (kg/m
2) 23.56 ± 2.53 24.00 ± 2.73 0.001 22.45 ± 2.35 23.28 ± 2.42 0.003
Waist circumference (cm) 82.62 ± 6.29 82.36 ± 7.47 0.729 80.83 ± 8.20 81.97 ± 8.01 0.320
Hip circumference (cm) 92.71 ± 5.36 93.32 ± 4.99 0.210 91.33 ± 6.48 93.43 ± 5.56 0.037
Waist-hip-ratio 0.89 ± 0.04 0.88 ± 0.05 0.129 0.88 ± 0.05 0.87 ± 0.05 0.358
SBP (mmHg) 129.10 ± 12.27 123.95 ± 12.41 0.018 130.42 ± 16.78 129.15 ± 12.36 0.622
DBP (mmHg) 76.15 ± 11.12 71.00 ± 11.11 0.075 73.53 ± 12.63 73.46 ± 8.58 0.974
Total cholesterol (mg/dL) 190.17 ± 36.27 192.83 ± 43.59 0.713 180.90 ± 32.04 178.73 ± 31.37 0.687
Triglyceride (mg/dL) 153.48 ± 74.23 147.65 ± 82.97 0.608 135.50 ± 78.50 139.77 ± 67.81 0.741
HDL-cholesterol (mg/dL) 42.94 ± 9.98 48.36 ± 14.55 0.003 45.97 ± 12.95 52.00 ± 15.66 0.028
LDL-cholesterol (mg/dL) 116.72 ± 30.74 112.76 ± 38.16 0.542 109.30 ± 28.56 100.61 ± 30.23 0.134
Fasting glucose (mg/dL) 181.42 ± 54.50 134.11 ± 34.10 < 0.001 186.56 ± 56.76 153.06 ± 40.17 0.002
HbA1C (%) 9.36 ± 2.15 8.09 ± 1.62 < 0.001 9.04 ± 1.61 8.13 ± 0.89 0.004
Kitt (%/min) 1.51 ± 0.53 2.63 ± 0.88 < 0.001 3.50 ± 0.75 2.75 ± 1.12 0.002
HOMA-IR 5.11 ± 1.56 1.38 ± 1.01 0.011 3.07 ± 1.86 1.62 ± 1.07 0.007
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low
density lipoprotein; Kitt, rate constant for glucose disappearance in the insulin tolerance test; HOMA-IR, homeostasis assessment
method for insulin resistance.
Values are presented as mean ± standard deviation.Mi Young Lee, et al.
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ous simpler methods similar to the euglycemic
hyperinsulinemic clamp method have been propos-
ed in recent years. HOMA-IR is easily calculated
from fasting glucose and insulin concentration,
and relates closely with euglycemic hyperinsuline-
mic clamp.
13,29 However, because insulin secretion
is pulsatile and HOMA-IR is not a dynamic test,
a single sample needs to be carefully interpreted.
30
On the other hand, Kitt is a reproducible, inexpen-
sive, and rapid method, allowing easy measure-
ment of insulin sensitivity.
5,6,31-33 In this study, we
performed HOMA-IR and Kitt to estimate insulin
sensitivity. As expected, both measurements for
insulin sensitivity were improved after TZDs treat-
ments. However, when we performed subgroup
analysis with baseline Kitt values, Kitt values
decreased in patients who showed Kitt values
above 2.5%/min at baseline, while fasting glucose
and HbA1C levels improved consistently in all
subjects. HOMA-IR was equally improved regard-
less of baseline Kitt values. We could not exactly
explain the reason of why Kitt values were not
consistently changed by the treatment of TZDs.
Nevertheless, we speculate various possibilities.
First, Kitt may fail to estimate insulin sensitivity
in insulin sensitive subjects. The amount of insulin
used for Kitt (0.1 U/kg) is a supraphysiological
dose and suppresses hepatic gluconeogenesis.
31
After insulin injection during Kitt measurement,
disappearance of glucose is mainly due to glucose
uptake by muscles or adipose tissue. Consequently,
Kitt may possibly underestimate the insulin sensi-
tivity when patients have hepatic insulin resistance
or show weak insulin resistance. In our study,
insulin sensitivity may be improved in insulin
sensitive subjects (Kitt > 2.5%/min) in a manner
similar to insulin resistant subjects, although Kitt
values did not change because of this reason.
Second, TZDs may affect glycemic control in insul-
in sensitive subjects by an another mechanism
rather than recovery of insulin resistance. It is well
known that both beta cell function and insulin action
are lessened in chronic hyperglycemic states
34,35
and reversed by improved glycemic control.
36,37 As
mentioned above, since TZDs have an additional
effect of preserving -cell function, β
20-22 TZDs may
improve the glycemic control by improving
glucose toxicity even if Kitt values did not im-
prove. Therefore, it is highly likely that the Kitt
rate did not improve when the baseline was above
2.5%/min. However, it is highly desirable to
perform clamp studies to clarify why Kitt is not
consistently changed, and this is the limitation of
the study.
In conclusion, Kitt could be a reliable method
to estimate the insulin sensitizing effects of TZDs
when Kitt values are less than 2.5%/min.
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